Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism
|
|
- Aubrey Hodge
- 6 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (1996) 11: Original Article Mephrology Dialysis Transplantation Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud, A. Martin-Malo, Y. Almaden, S. Tallon, M. T. Conception, A. Torres, A. Felsenfeld, P. Aljama and M. Rodriguez Servicio de Nefrologia, Unidad de nvestigacion, Hospital Universitario Reina Sofia Cordoba, Cordoba, Spain Abstract Background. Skeletal resistance to the calcaemic action of parathyroid hormone (PTH) is an important pathogenic factor in the development of secondary hyperparathyroidism. Since parathyroidectomy normalizes the calcaemic response to PTH in uraemic animals, the increase in PTH levels has been advanced as a cause of skeletal resistance to the calcaemic action of PTH. This study was designed to evaluate in uraemic rats the effect of normal PTH levels on the calcaemic response to PTH. Methods. To maintain normal PTH levels, rats were parathyroidectomized (PTX) and rat 1-34 PTH was infused at a rate of ug/100 g per hour via a subcutaneously implanted miniosmotic pump; this rate of infusion was considered to be the normal PTH replacement dose since it normalized serum calcium and phosphorus in PTX rats with normal renal function. Two separate studies were performed. n the first study, rats were maintained on a moderate-phosphorus (0.6%) diet and rats were divided into four groups: () normal; () uraemic; () PTX with normal PTH replacement; and (V) uraemic with PTX and normal PTH replacement. n a second study, the groups were the same except that a high-phosphorus (1.2%) diet was given to increase the magnitude of hyperparathyroidism in rats with intact parathyroid glands; an additional group (V) identical to group V except that rats received daily calcitriol was included. After 14 days, rats received a 48-h infusion of high-dose rat 1-34 PTH (0.11 ug/100 g per hour) to evaluate the calcaemic response to PTH. Results. The calcaemic response to PTH was similar in normal rats and PTX rats with PTH replacement on both a moderate and high-phosphorus diet. n uraemic rats, the calcaemic response to PTH was decreased and the maintenance of normal PTH levels by PTH replacement did not correct the decreased calcaemic response to PTH; moreover, calcitriol supplementation did not improve the calcaemic Correspondence and offprint requests to: Mariano Rodriguez MD, Unidad de nvestigacion, Hospital Universitario Reina Sofia, Avd. Menendez Pidal s n, Cordoba 14004, Spain. response to PTH. Finally, hypocalcaemia was observed in uraemic rats with PTH replacement and was more profound than in rats on a high-phosphorus diet. Conclusions. This study demonstrates that the maintenance of a normal PTH level in uraemic rats did not correct the impaired calcaemic response to PTH, suggesting that factors intrinsic to uraemia, independent of phosphorus, calcitriol, and PTH participate in the decreased calcaemic response to PTH in uraemia. Key words: phosphorus; PTH; secondary hyperparathyroidism; skeletal resistance; uraemia ntroduction Skeletal resistance to the calcaemic action of parathyroid hormone (PTH) is an important pathogenic factor in the development of secondary hyperparathyroidism [1-5]. n renal failure, serum calcium is often decreased despite markedly increased PTH levels. This is in part due to a decreased bone response to the calcaemic action of PTH. Several factors have been reported to contribute to the decreased calcaemic response to PTH in uraemia. These include phosphorus retention [6-8], a calcitriol deficiency [9,10], high- PTH-induced downregulation of the PTH receptor [10,11], and other factors intrinsic to uraemia [12]. Studies in uraemic animals with secondary hyperparathyroidism have shown that the elimination of circulating PTH by parathyroidectomy (PTX) corrects the impaired calcaemic response to PTH [ 10,11 ]. These results have been interpreted to suggest that the high PTH levels downregulate the bone PTH receptor. Moreover recent reports have shown that the expression of the PTH receptor mrna is decreased in kidney, liver, heart, and bone of uraemic rats with secondary hyperparathyroidism [13-16]; however it remains to be evaluated whether the expression of the PTH receptor protein is also decreased in uraemia. Recently it has been demonstrated that in vitamin-ddeficient rats [17], there is a dissociation between gene message, its final product, and the transduction system. Z 1996 European Dialysis and Transplant Association-European Renal Association
2 Abnormal calcaemic response to PTH in uraemia While it may be attractive to attribute the decreased calcaemic response to PTH in uraemia to the high PTH levels, Bover et al. [12] have recently reported that the prevention of secondary hyperparathyroidism in uraemic rats by dietary phosphorus restriction did not normalize the calcaemic response to PTH. Moreover these investigators observed that the calcaemic response to PTH was decreased in uraemic PTX rats as compared with PTX rats with normal renal function. Another finding that has questioned the role of high PTH levels as the cause of downregulation of the PTH receptor is the recent report by Urefla et al. [18] in which it was observed that in uraemic rats, PTH receptor mrna was decreased despite PTX. Thus these latter results would suggest that the mechanism by which PTX restores the calcaemic response to PTH to normal in uraemia may not be due to downregulation of the PTH receptor. The aim of this study was to evaluate the independent roles of sustained elevation of PTH levels and uraemia on the calcaemic response to PTH. To accomplish these goals, the calcaemic response to PTH was evaluated in both normal and uraemic rats with either intact parathyroid glands or PTX receiving a replacement dose of PTH. Subjects and methods The study was performed in male Wistar rats weighing g. Rats were placed in individual cages and underwent either sham operation or two-stage 5/6 nephrectomy; the latter was accomplished by ligation of two of the three main arteries of the left kidney followed one week later by right nephrectomy. Selective PTX was performed in one-half of the sham-operated and one-half of the 5/6 nephrectomized rats. This surgical intervention was done at the time of either the sham-operation or the arterial ligation; the PTX was considered successful only if the serum calcium was lower than 7.0 mg/dl 3 days after PTX. Before the initiation of the study period all rats received a 0.6% calcium, 0.6% phosphorus diet. The dose of PTH required for hormonal replacement was assessed in preliminary experiments in PTX rats with normal renal function. Parathyroidectomized rats received a continuous administration of rat 1-34 PTH (Bachem, Torrance, California, USA) using a subcutaneously implanted miniosmotic Alzet pump (model 2002, Alza, Palo Alto, California, USA). To determine the normal replacement dose, variable doses of PTH (0.011, 0.018, 0.022, 0.044, and 0.11 ug/100 g per hour) were infused in PTX rats fed a 0.6% calcium, 0.6% phosphorus diet. The continuous infusion of ug/100 g per hour of rat PTH increased the serum calcium to the mg/dl range and this level was maintained throughout the 14-day study period. The administration of lower PTH doses did not normalize the serum calcium and higher doses produced hypercalcaemia. n previous studies in uraemic rats, we and others have shown that a high-phosphorus diet induced marked elevations in PTH [8,10,12,19]. Thus a high-phosphorus diet was used to enhance secondary hyperparathyroidism; however, since phosphorus retention may directly affect the calcaemic response to PTH, the experimental design included two separate studies in which rats were fed 14 g of food daily of 1293 either a moderate-phosphorus diet (P 0.6%, Ca 0.6%) or a high-phosphorus diet (P 1.2%, Ca 0.6%); the vitamin D content of both diets was 100 U/100 g of diet. The experimental design of both studies is shown in Figure 1 and is described below. Study 1. Calcaemic response to PTH in uraemic rats fed a moderate-phosphorus diet The following four groups were evaluated: (1) group (sham operated), sham operated rats with intact parathyroid glands; (2) group (Nx), 5/6 nephrectomized rats with intact parathyroid glands; (3) group (sham operated with continuous ), PTX rats with normal renal function and PTH replacement; and (4) group V (Nx with continuous ), 5/6 nephrectomized PTX rats with PTH replacement. After 14 days on the moderatephosphorus diet, the calcaemic response to PTH was evaluated in the four groups. The method used to assess the calcaemic response to PTH has been described in our previous studies [8,10,12]. Briefly, after a 12-h fast, rat 1-34 PTH was administered via a subcutaneously implanted Alzet pump (model 2001) at a constant rate of 0.11 ug/100 g per hour for 48 h. During the, rats were fed a calciumfree and low-phosphorus (0.16%) diet to prevent intestinal absorption of calcium and avoid the inhibitory effect of phosphorus on the bone release of calcium [8]. Blood for measurement of serum calcium, phosphorus and creatinine was obtained immediately before and after the. Serum PTH levels were determined in rats with intact parathyroid glands immediately before the 48-h. Study 2. Calcaemic response to PTH in uraemic rats fed a high-phosphorus diet n this second study the groups were identical to those described in study 1 except that rats received a highphosphorus diet to enhance the development of secondary hyperparathyroidism. The following groups were included: (1) group (sham operated); (2) group (Nx); (3) group (sham operated with continuous ); and (4) group V (Nx with continuous ). Since in the last group the serum calcitriol level was lower than in the Nx group (52±7 versus 74±5 pg/ml, /><0.05), a fifth group (Nx with continuous plus calcitriol) was added to evaluate whether a calcitriol deficiency could be responsible for some of the difference in the calcaemic response to PTH. n this group a daily dose of calcitriol (20pmol) was administered subcutaneously throughout the entire experimental period including the last 48 h in which the calcaemic response to PTH was evaluated. This dose of calcitriol has been shown to increase calcitriol levels and decrease parathyroid cell proliferation without producing hypercalcaemia in uraemic rats [20]. During the last 48 h of study the rats underwent to assess the calcaemic response as described in study 1. n addition, serum calcitriol levels were determined before the 48-h in a subgroup of rats from the Nx (n = 7) and Nx with continuous («= 7) groups. Serum calcium, phosphorus, and creatinine were measured using standard automated laboratory techniques. ntact PTH was measured with an RMA assay specific for rats (Nichols, San Juan Capistrano, California, USA); the intra- and interassay coefficients of variation were 5.8% and 9% respectively. With this assay we were unable to quantify serum PTH in rats receiving an exogenous. Serum calcitriol
3 1294. Berdud et al. Group 1 Group Group Group V Sham 5/6Nx Sham+PTX 5/6Nx+PTX * PTH inf (0.022 pg/100 g/h) PTH inf (0.022 fjg/100 g/h) Moderate-phosphorus diet (P,0.6%; Ca,0.6%) PTH inf (0.11/vg/100g/h) Low-phosphorus, low-calcium diet (P,0.16%;Ca,0%) DAY STUDY 2. High-phosphorus diet Group Group Group Group V Group V Sham 5/6Nx Sham+PTX 5/6Nx+PTX 5/6NX+PTX PTH inf (0.022 /;g/100 g/h) PTH inf (0.022 ughoo g/h) PTH inf (0.022 ughoo g/h) + calcitriol(20 pmol/day) High-phosphorus diet (P,1.2%; Ca,0.6%) ) [ f j PTH inf (0.11 ^g/100g/h) Low-phosphorus, low-calcium diet (P,0.16%;Ca,0%) DAY Fig. 1. Schematic representation of the study protocols. Sham, Sham operation; 5/6Nx, 5/6 nephrectomy; PTX, selective parathyroidectomy. was measured with a radioreceptor assay (Nichols, San Juan Capistrano, California, USA); the intra- and interassay coefficients of variation were 7.2% and 10.4% respectively. Statistical analysis Differences between the means of groups on the same phosphorus diet were evaluated by one-way ANOVA followed by a multiple comparison test (Duncan). A P value <0.05 was considered significant. Results are expressed as the mean + SE. Results Calcaemic response to PTH in uraemic rats fed a moderate-phosphorus diet After 14 days on a moderate-phosphorus diet, the serum calcium was similar in rats with normal renal function, Nx rats with intact parathyroid glands, and rats with normal renal function with PTH replacement; in contrast, serum calcium was significantly decreased (P<0.01) in the Nx-PTH replaced group (Figure 2A, Table 1). Serum PTH levels were approximately sixfold greater (/><0.05) in Nx rats ( pmol) than rats with normal renal function rats ( pmol). After the 48-h, the serum calcium and the delta calcium (calcaemic response to PTH) were greater CP<0.05) in the two groups with normal renal function than in the two Nx groups (Figures 2A, B). Furthermore, no difference in the delta calcium was observed among parathyroid intact and the PTH replaced groups for the same renal function; however, there was an approximate sixfold difference in PTH levels between the two Nx groups. Before the PTH infusion test, the serum phosphorus level was elevated in the Nx-PTH replaced group (i><0.05); after the the serum phosphorus decreased to similar levels in all groups (Table 1). The calcaemic response to PTH in uraemic rats fed a high-phosphorus diet After 14 days on a high-phosphorus diet, the serum calcium was greater (P<0.05) in the group of rats with normal renal function and intact parathyroid glands than in the other four groups and lower (P<0.05) in the Nx-PTH replaced group than the other four groups (Table 2, Figure 3). After the 48-h the serum calcium and the delta calcium were greater (/><0.05) in the two groups with normal renal function than the three Nx groups; moreover, among the Nx groups, the delta calcium was less (P<0.05) in the parathyroid intact than the two groups with PTH replacement (Table 2, Figure 3). The PTH level in Nx rats with intact parathyroid glands was more than sixfold greater than in the group with normal renal function and intact parathyroid glands ( versus pmol, P< 0.001). Before the, the serum phosphorus was greater in rats with normal renal function and PTH replacement than in normal renal function with intact parathyroid glands ( versus mmol, P<0.001), but less than in the three Nx groups (Table 2). n all i
4 Abnormal calcaemic response to PTH in uraemia A B S.C«lcium (mm) Delta Ca 2 (mm) abc Sham op. Nx Sham op. Nx a abc Continuous PTH nfusion b i ae Sham op. Nx Sham op. Nx Continuous PTH nfusion DBasal DAfterPTH Fig. 2. Serum calcium concentration in rats before and after a 48-h test (0.11 ug/100 g per hour) (A), and the corresponding delta calcium (B) in different groups of rats fed a moderatephosphorus diet (P = 0.6%). Nx, 5/6 nephrectomized rats. Groups with continuous are parathyroidectomized rats with exogenous rat PTH replacement (0.022 ug/100 g per hour). Results are mean±se; P<0.05 versus (a) sham operated, (b) Nx, (c) sham operated with continuous. groups the serum phosphorus decreased to similar levels after the 48-h. Discussion The present study was designed to determine the effect of a fixed, normal dose of PTH on the calcaemic response to PTH in uraemic rats. n these rats, this fixed dose of PTH would prevent the development of secondary hyperparathyroidism. Our results indicate Table 1. Moderate-phosphorus diet 1295 that normal PTH levels in uraemic rats did not correct the calcaemic response to PTH. Moreover normal PTH levels were unable to maintain a normal serum concentration of calcium and phosphorus in uraemic rats on a moderate-phosphorus diet and both non-uraemic and uraemic rats on a high-phosphorus diet. Our results would suggest that in uraemia the decreased calcaemic response to PTH is not due to a downregulation of PTH receptor by high PTH levels. Therefore additional factors intrinsic to uraemia likely contribute to the decreased calcaemic response to PTH. n rats on a moderate-phosphorus diet, our PTH replacement dose (0.022 ug/100 g per hour) resulted in a normal serum calcium and phosphorus level in rats with normal renal function. Lower PTH doses resulted in hypocalcaemia and higher PTH doses in hypercalcaemia. Thus, even though the PTH level could not be measured with a conventional assay, the PTH dose used as a replacement dose in the PTX groups would appear to be appropriate for the maintenance of calcium and phosphorus homeostasis in the normal rat. Since in PTX rats the PTH replacement dose was fixed, this would prevent the development of secondary hyperparathyroidism during uraemia irrespective of the demands of the system. Thus, high PTH levels inducing downregulation of the PTH receptor should be prevented. The consequences of preventing an increase in PTH levels when demands are placed on the system for calcium and phosphorus homeostasis are demonstrated by the serum calcium and phosphorus concentration after 14 days of study diet. n rats with PTH replacement and normal renal function, a normal serum calcium and-phosphorus concentration was maintained when rats received a moderate-phosphorus diet, but hypocalcaemia and hyperphosphataemia were observed in rats on a high-phosphorus diet. t must be assumed that the inability to increase PTH levels during phosphorus loading resulted in hypocalcaemia and hyperphosphataemia even when renal function was normal; this assumption is based on the fact that normal rats with intact parathyroid glands on a highphosphorus diet were able to maintain a normal serum calcium and phosphorus and this result was presumably due to the threefold increase in PTH levels. n uraemic rats, the results were more dramatic. n the uraemic rats on a moderate phosphorus diet, a modest Groups Sham op. ("=12) Nx Sham op. + continuous Nx +continuous S. creatinine (umol) S. calcium before (mmol) S. calcium after S. phosphorus before (mmol) S. phosphorus after " ' b " ±3.1 ac 2.17±0.05 abc 3.12±0.07 abc 2.86±0.13 abc P<0.05 versus a sham operated, b Nx, c sham operated plus continuous.
5 1296 Table 2. High-phosphorus diet 1. Berdud el al Groups Sham op. («=14) Nx («= 7) Sham op. + continuous (" = 1D Nx + continuous («= 7) Nx+continuous + Calcitriol (n=10) Creatinine (umol) Calcium before (mmol) Calcium after Phosphorus before (mmol) Phosphorus after ± " " " " " " "" "' 1.62±0.07 abc " c "' " c l ac "" cd ac / > <0.05 versus * sham operated, " Nx, c sham operated with continuous, d Nx with continuous. A S. Calcium (mm) B Delta Ca (mm) bed Sham op. Nx Sham op. Nx Nx+Calcltrlol a Continuous b be CD Basal CH After PTH be Sham op. Nx Sham op. Nx Nx+Calcltrlol t Continuous Fig. 3. Serum calcium concentration in rats before and after a 48-h period test (0.11 ug/loog per hour) (A), and the corresponding delta calcium (B) in different groups of rats fed a high-phosphorus diet (P=1.2%). Nx, 5/6 nephrectomized rats. Groups with continuous are parathyroidectomized rats with exogenous rat PTH replacement (0.022 ug/100 g per hour). The Nx +calcitriol group received calcitriol (20 pmol/day) in addition to the continuous. Results are mean + SE, P < 0.05 versus (a) sham operated, (b) Nx, (c) sham operated with continuous (d) Nx with continuous. decrease in serum calcium was observed in the PTH replacement group, but not in the group with intact parathyroid glands; in the latter group, an approximately sixfold increase in PTH was able to maintain a normal serum calcium. n the uraemic rats on a highphosphorus diet, hypocalcaemia and hyperphosphataemia were observed in the parathyroid intact group despite an almost 20-fold increase in PTH levels; however, in uraemic rats with PTH replacement, the hypocalcaemia was considerably more profound. Thus these results demonstrate that a distinct failure to regulate serum calcium and phosphorus is present in uraemia when PTH levels are unable to adapt to the demands of the system [21]. An evaluation of the calcaemic response to PTH clearly shows that distinct differences were present among the groups. The calcaemic response to PTH was similar in the two groups with normal renal function on a moderate-phosphorus diet. This result was not unexpected since both groups were designed to have similar PTH levels; moreover, a similar calcaemic response to PTH serves to demonstrate that calcium metabolism in the PTH replacement group was similar to the group with intact parathyroid glands. n non-uraemic rats on a high-phosphorus diet, the PTH level was increased (approximately threefold greater than non-uraemic rats on a moderatephosphorus diet) and still the calcaemic response to PTH was similar to non-uraemic rats on the same diet receiving a normal replacement dose of PTH. Thus a presumed threefold increase in PTH levels did not decrease the calcaemic response to PTH in rats with normal renal function. n the first study in which rats were fed a moderatephosphorus diet, uraemic rats had a decreased calcaemic response as compared with the non-uraemic rats and it was not corrected by normal PTH levels. This suggests that uraemia rather than high PTH was responsible for the decreased calcaemic response to PTH. t is also likely that the decreased calcaemic response to PTH in uraemic rats with PTH replacement was in part responsible for the observed hypocalcaemia. The cause of the decreased calcaemic response to PTH was probably not due to hyperphosphataemia, since the 48-h was performed with rats on a low-phosphorus diet and the post-infusion serum phosphorus level were similar in all groups. Thus uraemia per se may have been a contributing factor. n the second study, rats were fed a high-phosphorus diet which enhanced the severity of secondary hyperparathyroidism as demonstrated by the fact that in uraemic rats on a high-phosphorus diet, PTH levels were more than threefold greater than uraemic rats on a moderate-phosphorus diet ( versus pmol). Similar to rats fed a moderatephosphorus diet (study 1), the calcaemic response to
6 Abnormal calcaemic response to PTH in uraemia PTH was less in the uraemic than the normal renal function rats. Among uraemic rats the calcaemic response to PTH was also less in the parathyroid intact than the PTH replacement group and this difference cannot be attributed to phosphorus, since both groups had a similar degree of hyperphosphataemia. One possible interpretation is that this difference in the calcaemic response to PTH was due to a PTH induced downregulation of bone PTH receptors in the uraemic rats with intact parathyroid glands and markedly increased PTH. However, a second explanation for this observation could be that the high degree of bone remodelling in parathyroid-intact uremic rats [22] could have affected the calcaemic response to PTH since Parfitt [23,24] has postulated that the homeostatic process which maintains the serum calcium concentration is dependent on the extent of quiescent bone surfaces. Earlier studies in uraemic animals have demonstrated that PTX restored the calcaemic response to PTH to normal [10,11] and thus suggested that downregulation of PTH receptors was induced by high PTH levels. Although a decreased expression of PTH receptors have been shown to be present in uraemic animals [13-16] and could have been due to high PTH levels, Urena et al. [18] have reported that a decreased expression of PTH receptor mrna was observed even in PTX uraemic rats and thus the decreased expression of PTH receptor mrna could not be caused by high PTH levels. While decreased expression of PTH receptor mrna is one of the mechanisms of downregulation, in the present study the term downregulation refers to abnormal receptor function directly caused by continuous exposure of the receptor to high PTH levels. n the study by Bover et al. [12] in which hyperparathyroidism was prevented by a phosphorusrestricted diet, the calcaemic response to PTH was decreased in uraemic rats despite normal PTH levels and among PTX rats, the calcaemic response was lower in uraemics than normals. Thus, by demonstrating that the calcaemic response to PTH was decreased in uraemic rats despite normal PTH levels, the present study provides evidence that this decrease in calcaemic response cannot be explained by the high PTH levels, and it would appear that downregulation of PTH receptor due to high PTH levels does not play a major role in the decreased calcaemic response to PTH in uraemia. Some previous studies have reported that calcitriol supplementation improves the calcaemic response to PTH in uraemia [8,9], but this finding was not confirmed by others [10]. n the present study, calcitriol supplementation did not improve the calcaemic response to PTH. t is possible that calcitriol may increase the calcaemic response by decreasing bone remodelling [25-27]; however, this effect would be difficult to observe in the present study if in our nephrectomized PTX rats with PTH replacement receiving calcitriol, bone turnover was not increased due to the normal PTH level. n conclusion, this study demonstrates that the main tenance of normal PTH levels in uraemic rats did not correct the impaired calcaemic response to PTH. Moreover, our findings would indicate that uraemia, independent of PTH and calcitriol, resulted in a decreased calcaemic response to PTH. Finally, it is unlikely that high PTH levels are a critical factor in the decreased calcaemic response to PTH observed in uraemia. Acknowledgements. This work was supported by grant from FSS (93/0527) and Fundacion Reina Sofia-CajaSur. References 1. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JM, Coburn JW. Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause of secondary hyperparathyroidism. J Clm Endocrinol Metab 1975; 41: Massry SG, Coburn JW, Lee DBW, Jowsey J, Kleeman CHR. Skeletal resistance to parathyroid hormone in renal failure: study in 105 human subjects. Ann ntern Med 1973; 78: Feinfeld DA, Sherwood LM. Parathyroid hormone and 1,25(OH) 2 D 3 in chronic renal failure. Kidney nt 1988; 33: Delmez JA, Slatopolsky E. Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1991; 72: Kaplan MA, Canterbury JM, Gavellas G et al. The calcemic and phosphaturic effects of parathyroid hormone in the normal and uremic dog. Metabolism 1978; 27: Somerville PJ, Kaye M. Evidence that resistance to the calcemic action of parathyroid hormone in rats with acute uremia is caused by phosphate retention. Kidney nt 1979; 16: Somerville PJ, Kaye M. Action of phosphorus on calcium release in isolated perfused rat tail. Kidney nt 1982; 22: Rodriguez M, Martin-Malo A, Martinez ME, Torres A, Felsenfeld AJ, Llach F. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney nt 1991; 40: Massry SG, Stein R, Garty J et al. Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25(OH) 2 D 3. Kidney nt 1976; 9: Rodriguez M, Felsenfeld A, Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kidney nt 1991; 40: Galceran T, Martin K, Morrissey JJ, Slatopolsky E. Role of 1,25 dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. Kidney nt 1987; 32: Bover J, Jara A, Trinidad P, Rodriguez M, Martin-Malo A, Felsenfeld AJ. The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia. Kidney nt 1994; 46: Ureiia P, Kubrusly M, Mannstadt M et al. The renal PTH/PTHrP receptor is down regulated in rats with chronic renal failure. Kidney nt 1994; 45: Tian J, Smogorzewski M, Kedes L, Massry S. The renal PTH/PTHrP receptor is down regulated in rats with chronic renal failure. Am J Nephrol 1994; 14: Ureiia P, Ferreira A, Moreux C, Me de Vernejoul. PTH/PTHr receptor mrna is down regulated in epiphyseal cartilage growth plate of uremic rats. J Bone Miner Res 1995; 10: S514 (Abstract) 16. Smogorzewski M, Tian J, Masrry SG. Down-regulation of PTH- PTHrP receptor of heart in CRF: Role of [Ca 2+ ]. Kidney nt 1995; 47: Turner G, Coureau C, Rabin MR et al. Parathyroid hormone (PTH)/PTH-related protein receptor messenger ribonucleic acid expression and PTH response in a rat model of secondary hyperparathyroidism associated with vitamin D deficiency. Endocrinology 1995; 136: Urena P, Mannstadt M, Hruby M et al. Parathyroidectomy
7 1298. Berdud etal. does not prevent renal PTH/PTHrP receptor down-regulation 23. Parfitt AM. Bone and calcium homeostasis. Bone 1987; 8[Suppl in uremic rats. Kidney nt 1995; 47: ]: S1-S8 19. Bover J, Rodriguez M, Trinidad P et al. Factors in the development of secondary hyperparathyroidism during graded renal a new approach to the homeostatic function of bone lining cells. 24. Parfitt AM. Plasma calcium control at quiescent bone surfaces: failure in the rat. Kidney nt 1994; 45: Bone 1989; 10: Szabo A, Merke J, Beir E, Mall G, Ritz E. 1,25 (OH) 2 vitamin 25. Goodman WG, Ramirez JA, Belin TR et al. Development of D 3 inhibits parathyroid cell proliferation in experimental uremia. adynamic bone in patients with secondary hyperparathyroidism Kidney nt 1989; 35: after intermittent calcitriol therapy. Kidney nt 1994; 46: 21. Kurokawa K. Calcium-regulating hormones and the kidney Kidney nt 1987; 32: Pahl M, Jara A, Bover J, Felsenfeld AJ. Studies in a hemodialysis 22. Felsenfeld AJ, Machado L, Bover J, Trinidad P, Rodriguez M. patient indicating that calcitriol may have a direct suppressive Effect of aluminium on the development of hyperparathyroidism effect on bone. Nephron 1995; 71: and bone disease in the azotaemic rat. Nephrol Dial Transplant 27. Salusky B, Ramirez JA, Belin T et al. Pulse calcitriol therapy: 1993; 8: a randomized trial. J Am Soc Nephrol 1994; 5: 855. (Abstract) Received for publication: Accepted in revised form:
The calcemic response to PTH in the rat: Effect of elevated PTH levels and uremia
Kidney International, Vol. 46 (1994), pp. 310 317 LABORATORY INVESTIGATION The calcemic response to PTH in the rat: Effect of elevated PTH levels and uremia J0RDI BOVER, AQUILES JARA, PEDRO TRINIDAD,1
More informationRelative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats
Kidney International, T/ol. 49 (1996), pp. 1441 1446 Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats SERAFIN TALLON, ISABEL BERDUD, ALEXIS HERNANDEZ,
More informationThis review examines the dynamics of parathyroid hormone
In-Depth Review Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Arnold J. Felsenfeld,* Mariano Rodríguez, and Escolástico Aguilera-Tejero *Department of Medicine,
More informationHyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal and Azotemic Rats
Original Paper Nephron 2002;92:883 888 DOI: 10.1159/000065454 Accepted: May 22, 2002 Hyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationRegulation of PTH1 receptor expression by uremic ultrafiltrate in UMR osteoblast-like cells
Kidney International, Vol. 65 (24), pp. 897 93 Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 16 1 osteoblast-like cells SINEE DISTHABANCHONG, HATIM HASSAN, CHARLES L. MCCONKEY,
More informationEffect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
Nephrol Dial Transplant (2003) 18 [Suppl 3]: iii42 iii46 DOI: 10.1093/ndt/gfg1011 Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients Kazuhiro Shiizaki
More informationDifferent effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism
Nephrol Dial Transplant (996) : 8-87 Original Article Nephrology Dialysis Transplantation Different effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationSigmoidal relationship between calcitonin and calcium: Studies in normal, parathyroidectomized, and azotemic rats
Kidney International, Vol 4 (1991), pp 7 74 igmoidal relationship between calcitonin and calcium: tudies in normal, parathyroidectomized, and azotemic rats ARMANDO To1uus,1 MARIANO RODRIGUZ, ARNOLD FLNFLD,
More informationGuidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism
Nephrol Dial Transplant (16) 11 [Suppl 3]: 6-101 Nephrology Dialysis Transplantation Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism E. Fernandez 1 and F.
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationConsiderations for the Treatment of Secondary Hyperparathyroidism in Renal Failure
DISEASEOF THE MONTH Considerations for the Treatment of Secondary Hyperparathyroidism in Renal Failure ARNOLD J. FELSENFELD Department of Medicine, West Los Angeles Veterans Affairs Medical Center, and
More informationProliferation in hyperplastic human and normal rat parathyroid glands: Role of phosphate, calcitriol, and gender
Kidney International, Vol. 64 (2003), pp. 2311 2317 Proliferation in hyperplastic human and normal rat parathyroid glands: Role of phosphate, calcitriol, and gender YOLANDA ALMADEN, ARNOLD J. FELSENFELD,
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationThe influence of acute and chronic hypercalcemia on the parathyroid hormone response to hypocalcemia in rabbits
European Journal of Endocrinology (2002) 146 411 418 ISSN 0804-4643 EXPERIMENTAL STUDY The influence of acute and chronic hypercalcemia on the parathyroid hormone response to hypocalcemia in rabbits S
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationThe Effect of Long-Term Intravenous Calcitriol Administration on Parathyroid Function in Hemodialysis
The Effect of Long-Term Intravenous Calcitriol Administration on Parathyroid Function in Hemodialysis 12 Mariano Rodriguez,3 Arnold J. Felsenfeld, Carl Williams, James A. Pederson, and Francisco Liach
More informationHypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS
Nephrol Dial Transplant (2007) 22: 1658 1664 doi:10.1093/ndt/gfm008 Advance Access publication 13 February 2007 Original Article Hypercalcaemia is associated with poor mental health in haemodialysis patients:
More informationTotal Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism
The Journal of International Medical Research 2011; 39: 978 987 Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism J NARANDA 1,2, R EKART
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationEffect of Direction and Rate of Change of Calcium on Parathyroid Hormone Secretion in Uraemia
Nephrol Dial Transplant (1989) 4: 339-344 1989 European Dialysis and Transplant Association-European Renal Association Nephrology Dialysis Transplantation Original Article Effect of Direction and Rate
More informationInfluence of parathyroid mass on the regulation of PTH secretion
http://www.kidney-international.org & 26 International Society of Nephrology Influence of parathyroid mass on the regulation of PTH secretion E Lewin 1,2 and K Olgaard 2 1 Nephrological Department B, The
More informationCalcium-Sensing Receptor Expression and Parathyroid Hormone Secretion in Hyperplastic Parathyroid Glands from Humans
Calcium-Sensing Receptor Expression and Parathyroid Hormone Secretion in Hyperplastic Parathyroid Glands from Humans Sagrario Cañadillas,* Antonio Canalejo, Rafael Santamaría, Maria E. Rodríguez,* Jose
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Effect on mortality of elective parathyroid surgery in one hundred and three patients with chronic kidney disease : our experience. White Rose Research Online URL for this
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationBsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients
Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco
More informationCase Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
SAGE-Hindawi Access to Research International Nephrology Volume 211, Article ID 246734, 6 pages doi:1.461/211/246734 Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationRenal osteodystrophy with special emphasis on secondary hyperparathyroidism
RENAL OSTEODYSTROPHY WITH SPECIAL EMPHASIS ON SECONDARY HYPERPARATHYROIDISM Artigo Original Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 9-18 Renal osteodystrophy with special emphasis on secondary hyperparathyroidism
More information... . : ... PTH.
IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationAmol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through
Research Article ISSN: 0974-6943 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through www.jpronline.info Comparison of efficacy and safety of Cinacalcet versus Calcitriol
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1998) 13 [Suppl 3]: 57 61 Nephrology Dialysis Transplantation The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationSuppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism
Kidney International, Vol. 5] (1997), pp. 159 1595 Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism WILLIAM G. GOODMAN, JOHANNS
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationamino terminus of the hormone, detect not only PTH(1-84) Accepted for publication December 13, 2002
Kidney International, Vol. 63 (2003), pp. 1801 1808 CLINICAL NEPHROLOGY EPIDEMIOLOGY CLINICAL TRIALS Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays
More informationhypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause
hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),
More informationA. Fine,3 D. Cox, and B. Fontaine
Elevation of Serum Phosphate Affects Parathyroid Hormone Levels in Only 50% of Hemodialysis Patients, Which Is Unrelated to Changes in Serum Calcium1 2 A. Fine,3 D. Cox, and B. Fontaine A. Fine, D. Cox,
More informationInvestigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis
Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis Tutorial for Specialist Portfolio Biomedical Scientists 03/02/2014 Dr Petros Kampanis Clinical Scientist 1. Calcium Most abundant
More informationCinacalcet suppresses calcification of the aorta and heart in uremic rats
original article http://www.kidney-international.org & 28 International Society of Nephrology see commentary on page 1229 Cinacalcet suppresses calcification of the aorta and heart in uremic rats Takehisa
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationPTH increases renal 25(OH)D 3-1 -hydroxylase (CYP1 ) mrna but not renal 1,25(OH) 2 D 3 production in adult rats
Am J Physiol Renal Physiol 284: F1032 F1036, 2003; 10.1152/ajprenal.00306.2002. PTH increases renal 25(OH)D 3-1 -hydroxylase (CYP1 ) mrna but not renal 1,25(OH) 2 D 3 production in adult rats H. J. Armbrecht,
More informationDifferences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease
Kidney International, Vol. 64 (2003), pp. 737 742 Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease B. PETER SAWAYA, REZKALLA
More informationCellular mechanisms of renal osteodystrophy
Kidney International, Vol. 56, Suppl. 73 (1999), pp. S-8 S-13 Cellular mechanisms of renal osteodystrophy JUDITH A. HOYLAND and MICHAEL L. PICTON Musculoskeletal Research Group, University of Manchester
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2006) 21: 1663 1668 doi:10.1093/ndt/gfl006 Advance Access publication 6 February 2006 Original Article Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism
More informationWhat Are the Targets in CKD-MBD?
Knowledge Exchange 2016 Paris, France, September 30, 2016 Date of preparation: Nov 2016 Item job code: INTSP/C-ANPROM/FOS/16/0025 Cristina Ortiz Jorge B Cannata-Andía Bone and Mineral Research Unit Hospital
More informationParathyroid Hormone: New Assays, New Receptors
Parathyroid Hormone: New Assays, New Receptors By Kevin J. Martin, Irme Akhtar, and Esther A. González Accurate measurements of parathyroid hormone (PTH) in plasma are necessary for the assessment, monitoring,
More informationK/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients
http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease
More informationClinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages 2 5 and on dialysis
Nephrol Dial Transplant (2017) 1 14 doi: 10.1093/ndt/gfx080 Special Report Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease stages
More informationDevelopment and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics
translational nephrology http://www.kidney-international.org & 2008 International Society of Nephrology Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from
More informationClinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2 5 and on dialysis
Nephrol Dial Transplant (2017) 32: 1114 1127 doi: 10.1093/ndt/gfx080 Advance Access publication 1 June 2017 Clinical practice recommendations for treatment with active vitamin D analogues in children with
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationin the treatment of peritoneal dialysis patients with renal osteodystrophy
1-α-hydroxy Hong Kong Journal vitamin of DNephrology 3 2001;3(2):74-78 ORIGINAL A R T I C L E Conversion of calcitriol to 1-α-hydroxy vitamin in the treatment of peritoneal dialysis patients with renal
More informationSince its inception in the 1970s, dialysis has allowed for
http://www.revistanefrologia.com 2013 Revista Nefrología. Official Publication of the Spanish Nephrology Society editorial comment See original article on page 46 Are the K/DOQI objectives for bone mineral
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism
More informationThe Control of Phosphate Exeretion in Uremia *
Journal of Clinical Investigation Vol. 5, No. 5, 19 The Control of Phosphate Exeretion in Uremia * E. SLATOPOLSKY, L. GRADOWSKA, C. KASHEMSANT, R. KELTNER, C. MANLEY, AND N. S. BRICKER t (From the Renal
More informationLinkage of Fibroblast Growth Factor 23 and Phosphate in Serum: Phosphate and Fibroblast Growth Factor 23 Reduction by Increasing Dose of Sevelamer
J Bone Metab 2018;25(3):153-159 https://doi.org/10.11005/jbm.2018.25.3.153 pissn 2287-6375 eissn 2287-7029 Original Article Linkage of Fibroblast Growth Factor 23 and Phosphate in Serum: Phosphate and
More informationRace Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients
J Am Soc Nephrol 11: 330 334, 2000 Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients AJAY GUPTA,* LEE R. KALLENBACH, GERARD ZASUWA,* and GEORGE W. DIVINE *Division of Nephrology
More informationComparison between Whole and Intact Parathyroid Hormone Assays
tap_926 42..49 Therapeutic Apheresis and Dialysis 15(Supplement 1):42 49 doi: 10.1111/j.1744-9987.2011.00926.x Therapeutic Apheresis and Dialysis 2011 International Society for Apheresis Comparison between
More informationSerum calcium and bone: effect of PTH, phosphate, vitamin D and uremia
revisiones http://www.revistanefrologia.com 2014 Revista Nefrología. Órgano Oficial de la Sociedad Española de Nefrología Serum calcium and bone: effect of PTH, phosphate, vitamin D and uremia Barton S.
More informationPathogenesis of secondary hyperparathyroidism
The International Journal of Artificial Organs / Vol. 32 / no. 2, 2009 / pp. 75-80 Review Pathogenesis of secondary hyperparathyroidism MARIO COZZOLINO, SABINA PASHO, GIUDITTA FALLABRINO, LAURA OLIVI,
More informationCell Biology of Parathyroid Gland Hyperplasia in Chronic Renal Failure
REVIEW J Am Soc Nephrol 11: 1141 1152, 2000 Cell Biology of Parathyroid Gland Hyperplasia in Chronic Renal Failure TILMAN B. DRÜEKE Institut National de la Santé et de la Recherche Médicale U507 and Division
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationRenal Osteodystrophy in Pediatric Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 20, 2004 Francisco J. Cano, Marcela Valenzuela, Pedro Zambrano, Marta A. Azocar, Eduardo Wolff, Maria A. Delucchi, Eugenio E. Rodriguez Renal Osteodystrophy in Pediatric
More informationAdvances in Peritoneal Dialysis, Vol. 22, 2006
Advances in Peritoneal Dialysis, Vol. 22, 2006 M. Carmen Sánchez González, 1 Fernando López Barea, 2 M. Auxiliadora Bajo, 1 Rafael Selgas, 1 for the Collaborators of the Multicenter Study Group* Serum
More informationParathyroid hormone and growth in children with chronic renal failure
Kidney International, Vol. 67 (2005), pp. 2338 2345 Parathyroid hormone and growth in children with chronic renal failure SIMON C. WALLER, DEBORAH RIDOUT, TOM CANTOR, and LESLEY REES Nephro-Urology Unit,
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationSkeletal. Parathyroid hormone-related protein Analyte Information
Skeletal Parathyroid hormone-related protein Analyte Information 1 2012-04-04 Parathyroid hormone related protein (PTHrP) Introduction Parathyroid hormone-related protein (PTHrP) is actually a family of
More informationImprovement of adynamic bone disease after renal transplantation
Brazilian Journal of Medical and Biological Research (2006) 39: 31-41 Adynamic bone disease after transplantation ISSN 0100-879X 31 Improvement of adynamic bone disease after renal transplantation K.A.
More informationThe Management of Phosphataemia in Renal Dogs or Cats
The Management of Phosphataemia in Renal Dogs or Cats improves both the quality of life and the life expectancy of animals. THE CARDIOLOGY - NEPHROLOGY DIMENSION PAIN INFLAMMATION ANTI-INFECTIVE PHOSPHATAEMIA
More informationRisk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism
Ho et al. BMC Nephrology (2017) 18:12 DOI 10.1186/s12882-016-0421-5 RESEARCH ARTICLE Open Access Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1998) 1: [Suppl ]: 68 7 Nephrology Dialysis Transplantation Intermittent oral 1a-hydroxyvitamin D is effective and safe for the suppression of secondary hyperparathyroidism in
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationA clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 6, 513 518, 2004 A clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients Seiji
More informationA non-(1 84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples
Clinical Chemistry 44:4 805 809 (1998) Endocrinology and Metabolism A non-(1 84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in
More informationSerum calcium and bone: effect of PTH, phosphate, vitamin D and uremia
http://www.revistanefrologia.com 2014 Revista Nefrología. Official Publication of the Spanish Nephrology Society Serum calcium and bone: effect of PTH, phosphate, vitamin D and uremia Barton S. Levine
More informationBEC FEED SOLUTIONS NEW ZEALAND Ltd
BEC FEED SOLUTIONS NEW ZEALAND Ltd Proudly sponsor Dr Alessandro Mereu Yara Feed Phosphates July 2017 NZARN Meeting www.becfeed.co.nz Phosphorus metabolism in cattle: principles and interactions with Ca
More information